Roquefort Therapeutics (LON:ROQ) Shares Down 2.1% – Here’s What Happened

Shares of Roquefort Therapeutics plc (LON:ROQ) were down 2.1% on Thursday . The stock traded as low as GBX 3.50 ($0.04) and last traded at GBX 3.77 ($0.05). Approximately 1,022,574 shares changed hands during trading, a decline of 21% from the average daily volume of 1,298,604 shares. The stock had previously closed at GBX 3.85 ($0.05).

Roquefort Therapeutics Price Performance

The stock has a market capitalization of £4.59 million, a price-to-earnings ratio of -355.60 and a beta of 0.05. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The stock has a fifty day moving average of GBX 4.30 and a 200-day moving average of GBX 4.12.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.